Weekly Analysts’ Ratings Changes for Kestra Medical Technologies (KMTS)

Several analysts have recently updated their ratings and price targets for Kestra Medical Technologies (NASDAQ: KMTS):

• 7/15/2026 – Kestra Medical Technologies was given a new $30.00 price target by Wolfe Research.
• 7/15/2026 – Kestra Medical Technologies had its price target raised by BTIG Research from $30.00 to $32.00. They now have a “buy” rating on the stock.
• 6/30/2026 – Kestra Medical Technologies was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/27/2026 – Kestra Medical Technologies was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/15/2026 – Kestra Medical Technologies was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Insider Activity at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $20.81, for a total value of $312,150.00. Following the sale, the insider owned 395,467 shares of the company’s stock, valued at $8,229,668.27. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 3.60% of the stock is currently owned by corporate insiders.

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.